Edition:
India

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

42.14USD
10:16pm IST
Change (% chg)

$-0.46 (-1.08%)
Prev Close
$42.60
Open
$42.49
Day's High
$42.52
Day's Low
$42.00
Volume
1,007,585
Avg. Vol
8,023,919
52-wk High
$46.46
52-wk Low
$34.32

Chart for

About

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $214,682.30
Shares Outstanding(Mil.): 5,955.13
Dividend: 0.32
Yield (%): 3.55

Financials

  PFE.N Industry Sector
P/E (TTM): 26.26 30.48 33.70
EPS (TTM): 1.37 -- --
ROI: 6.00 14.95 14.45
ROE: 13.80 16.27 15.96

Pfizer-Lilly drug shown to help reduce back pain in late-stage trial

A non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co succeeded in reducing chronic low back pain when used in a stronger dose, results from a late-stage study showed on Tuesday.

19 Feb 2019

UPDATE 1-Pfizer-Lilly drug shown to help reduce back pain in late-stage trial

Feb 19 A non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co succeeded in reducing chronic low back pain when used in a stronger dose, results from a late-stage study showed on Tuesday.

19 Feb 2019

Higher dose of Pfizer-Lilly drug helps reduce back pain in study

Feb 19 Pfizer and Eli Lilly said on Tuesday that a higher dose of their non-opioid drug tanezumab succeeded in reducing chronic low back pain in patients in a late-stage clinical study.

19 Feb 2019

Merck, Pfizer drug combo extends kidney cancer survival - study

A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday.

17 Feb 2019

Merck, Pfizer drug combo extends kidney cancer survival: study

A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday.

17 Feb 2019

Merck, Pfizer drug combo extends kidney cancer survival -study

Feb 16 A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday.

17 Feb 2019

Merck, Pfizer combo treatment boosts kidney cancer survival

NEW YORK Drugmaker Merck & Co Inc said on Monday that the combination of its cancer immunotherapy Keytruda with Pfizer Inc's Inlyta cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with chemotherapy drug Sutent.

12 Feb 2019

Merck, Pfizer combo treatment boosts kidney cancer survival

NEW YORK Drugmaker Merck & Co Inc said on Monday that the combination of its cancer immunotherapy Keytruda with Pfizer Inc's Inlyta cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with chemotherapy drug Sutent.

12 Feb 2019

Pfizer Japan recalls high blood pressure drug over cancer-causing impurity

TOKYO The Japanese subsidiary of Pfizer Inc is recalling a drug for high blood pressure which was found to contain a carcinogenic substance in its active ingredient valsartan, the drugmaker said on Friday.

09 Feb 2019

Pfizer Japan recalls high blood pressure drug over cancer-causing impurity

TOKYO The Japanese subsidiary of Pfizer Inc is recalling a drug for high blood pressure which was found to contain a carcinogenic substance in its active ingredient valsartan, the drugmaker said on Friday.

08 Feb 2019

Earnings vs. Estimates